Global Lisinopril  Market

Lisinopril  Comprehensive Study by Patient Age (Paediatric (6 to 17 years), Adult (above 18 years)), Form (Solution, Tablet), Sales Channel (Online, Offline, Hospital Pharmacy, Retail Pharmacy), Dosage (2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg) Players and Region - Global Market Outlook to 2030

Lisinopril  Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Lisinopril  Market Scope
Lisinopril is the synthetic peptide derivative, is chemically described as (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-Lproline dihydrate that falls under the angiotensin-converting enzyme (ACE) inhibitor class that aims to treat high blood pressure. Inhibition of ACE leads to reduction in plasma angiotensin II that suppresses the vasopressor activity thereby reducing the aldosterone secretion. Through reducing the blood pressure, the drug prevent from mild to severe strokes, and improve survival after cardiac arrest and kidney problems. Lisinopril functions through relaxing the blood vessel, which promotes blood flow. Lisinopril is a white to off-white coloured crystalline powder, which is soluble in water and insoluble in ethanol. Commercially, lisinopril is available in 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40mg dosage.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledLupin (India), Teva Pharmaceutical Industries Ltd. (Israel), Zhejiang Huahai Pharmaceutical Co. (China), Actavis, Inc. (United States), Apotex Inc. (Canada), Sun Pharmaceuticals Inc. (India), Evonik Industries (Germany), AstraZeneca PLC (United Kingdom), Sandoz (a Novartis company) (Switzerland) and Silvergate Pharmaceuticals, Inc. (United States)
CAGR4.3%


The global lisinopril market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lisinopril market.

Lupin (India), Teva Pharmaceutical Industries Ltd. (Israel), Zhejiang Huahai Pharmaceutical Co. (China), Actavis, Inc. (United States), Apotex Inc. (Canada), Sun Pharmaceuticals Inc. (India), Evonik Industries (Germany), AstraZeneca PLC (United Kingdom), Sandoz (a Novartis company) (Switzerland) and Silvergate Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Lisinopril  market by Type and Region with country level break-up.

On the basis of geography, the market of Lisinopril  has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In June 2019, CutisPharma acquired Silvergate Pharmaceuticals at an undisclosed sum. The acquisition has led in development of new corporate brand for the unified company namely, Azurity Pharmaceuticals. This strategic move aims to combine product portfolio and expertise of two strong companies with a rich legacy to cater the need of children and elderly patients.
In March 2020, AstraZeneca divests rights to Atnahs Pharma for its global commercial rights of the Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination). Under this agreement, AstraZeneca has received a payment of USD 350 million from Atnahs.


Influencing Trend:
Generic Versions and Cost-Effectiveness

Market Growth Drivers:
Growing prevalence of cardiac arrest and Rise in geriatric population experiencing higher rates of hypertension.

Challenges:
Rise in product recalls

Restraints:
Side effects associated with lisinopril

Opportunities:
Growing Awareness and Early Diagnosis and Increasing use of Combination Therapies

Key Target Audience
Manufacturers of lisinopril, Governmental bodies and Research Institutes

Report Objectives / Segmentation Covered

By Patient Age
  • Paediatric (6 to 17 years)
  • Adult (above 18 years)

By Form
  • Solution
  • Tablet

By Sales Channel
  • Online
  • Offline
  • Hospital Pharmacy
  • Retail Pharmacy

By Dosage
  • 2.5 mg
  • 5 mg
  • 10 mg
  • 20 mg
  • 30 mg
  • 40 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of cardiac arrest
      • 3.2.2. Rise in geriatric population experiencing higher rates of hypertension.
    • 3.3. Market Challenges
      • 3.3.1. Rise in product recalls
    • 3.4. Market Trends
      • 3.4.1. Generic Versions and Cost-Effectiveness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lisinopril , by Patient Age, Form, Sales Channel, Dosage and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lisinopril  (Value)
      • 5.2.1. Global Lisinopril  by: Patient Age (Value)
        • 5.2.1.1. Paediatric (6 to 17 years)
        • 5.2.1.2. Adult (above 18 years)
      • 5.2.2. Global Lisinopril  by: Form (Value)
        • 5.2.2.1. Solution
        • 5.2.2.2. Tablet
      • 5.2.3. Global Lisinopril  by: Sales Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
        • 5.2.3.3. Hospital Pharmacy
        • 5.2.3.4. Retail Pharmacy
      • 5.2.4. Global Lisinopril  by: Dosage (Value)
        • 5.2.4.1. 2.5 mg
        • 5.2.4.2. 5 mg
        • 5.2.4.3. 10 mg
        • 5.2.4.4. 20 mg
        • 5.2.4.5. 30 mg
        • 5.2.4.6. 40 mg
      • 5.2.5. Global Lisinopril  Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Lisinopril : Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Lupin (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Zhejiang Huahai Pharmaceutical Co. (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Actavis, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Apotex Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceuticals Inc. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Evonik Industries (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca PLC (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sandoz (a Novartis company) (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Silvergate Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lisinopril  Sale, by Patient Age, Form, Sales Channel, Dosage and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lisinopril  (Value)
      • 7.2.1. Global Lisinopril  by: Patient Age (Value)
        • 7.2.1.1. Paediatric (6 to 17 years)
        • 7.2.1.2. Adult (above 18 years)
      • 7.2.2. Global Lisinopril  by: Form (Value)
        • 7.2.2.1. Solution
        • 7.2.2.2. Tablet
      • 7.2.3. Global Lisinopril  by: Sales Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
        • 7.2.3.3. Hospital Pharmacy
        • 7.2.3.4. Retail Pharmacy
      • 7.2.4. Global Lisinopril  by: Dosage (Value)
        • 7.2.4.1. 2.5 mg
        • 7.2.4.2. 5 mg
        • 7.2.4.3. 10 mg
        • 7.2.4.4. 20 mg
        • 7.2.4.5. 30 mg
        • 7.2.4.6. 40 mg
      • 7.2.5. Global Lisinopril  Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lisinopril : by Patient Age(USD Million)
  • Table 2. Lisinopril  Paediatric (6 to 17 years) , by Region USD Million (2018-2023)
  • Table 3. Lisinopril  Adult (above 18 years) , by Region USD Million (2018-2023)
  • Table 4. Lisinopril : by Form(USD Million)
  • Table 5. Lisinopril  Solution , by Region USD Million (2018-2023)
  • Table 6. Lisinopril  Tablet , by Region USD Million (2018-2023)
  • Table 7. Lisinopril : by Sales Channel(USD Million)
  • Table 8. Lisinopril  Online , by Region USD Million (2018-2023)
  • Table 9. Lisinopril  Offline , by Region USD Million (2018-2023)
  • Table 10. Lisinopril  Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 11. Lisinopril  Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Lisinopril : by Dosage(USD Million)
  • Table 13. Lisinopril  2.5 mg , by Region USD Million (2018-2023)
  • Table 14. Lisinopril  5 mg , by Region USD Million (2018-2023)
  • Table 15. Lisinopril  10 mg , by Region USD Million (2018-2023)
  • Table 16. Lisinopril  20 mg , by Region USD Million (2018-2023)
  • Table 17. Lisinopril  30 mg , by Region USD Million (2018-2023)
  • Table 18. Lisinopril  40 mg , by Region USD Million (2018-2023)
  • Table 19. South America Lisinopril , by Country USD Million (2018-2023)
  • Table 20. South America Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 21. South America Lisinopril , by Form USD Million (2018-2023)
  • Table 22. South America Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 23. South America Lisinopril , by Dosage USD Million (2018-2023)
  • Table 24. Brazil Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 25. Brazil Lisinopril , by Form USD Million (2018-2023)
  • Table 26. Brazil Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 27. Brazil Lisinopril , by Dosage USD Million (2018-2023)
  • Table 28. Argentina Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 29. Argentina Lisinopril , by Form USD Million (2018-2023)
  • Table 30. Argentina Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 31. Argentina Lisinopril , by Dosage USD Million (2018-2023)
  • Table 32. Rest of South America Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 33. Rest of South America Lisinopril , by Form USD Million (2018-2023)
  • Table 34. Rest of South America Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 35. Rest of South America Lisinopril , by Dosage USD Million (2018-2023)
  • Table 36. Asia Pacific Lisinopril , by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 38. Asia Pacific Lisinopril , by Form USD Million (2018-2023)
  • Table 39. Asia Pacific Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 40. Asia Pacific Lisinopril , by Dosage USD Million (2018-2023)
  • Table 41. China Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 42. China Lisinopril , by Form USD Million (2018-2023)
  • Table 43. China Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 44. China Lisinopril , by Dosage USD Million (2018-2023)
  • Table 45. Japan Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 46. Japan Lisinopril , by Form USD Million (2018-2023)
  • Table 47. Japan Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 48. Japan Lisinopril , by Dosage USD Million (2018-2023)
  • Table 49. India Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 50. India Lisinopril , by Form USD Million (2018-2023)
  • Table 51. India Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 52. India Lisinopril , by Dosage USD Million (2018-2023)
  • Table 53. South Korea Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 54. South Korea Lisinopril , by Form USD Million (2018-2023)
  • Table 55. South Korea Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 56. South Korea Lisinopril , by Dosage USD Million (2018-2023)
  • Table 57. Taiwan Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 58. Taiwan Lisinopril , by Form USD Million (2018-2023)
  • Table 59. Taiwan Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 60. Taiwan Lisinopril , by Dosage USD Million (2018-2023)
  • Table 61. Australia Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 62. Australia Lisinopril , by Form USD Million (2018-2023)
  • Table 63. Australia Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 64. Australia Lisinopril , by Dosage USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Lisinopril , by Form USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Lisinopril , by Dosage USD Million (2018-2023)
  • Table 69. Europe Lisinopril , by Country USD Million (2018-2023)
  • Table 70. Europe Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 71. Europe Lisinopril , by Form USD Million (2018-2023)
  • Table 72. Europe Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 73. Europe Lisinopril , by Dosage USD Million (2018-2023)
  • Table 74. Germany Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 75. Germany Lisinopril , by Form USD Million (2018-2023)
  • Table 76. Germany Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 77. Germany Lisinopril , by Dosage USD Million (2018-2023)
  • Table 78. France Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 79. France Lisinopril , by Form USD Million (2018-2023)
  • Table 80. France Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 81. France Lisinopril , by Dosage USD Million (2018-2023)
  • Table 82. Italy Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 83. Italy Lisinopril , by Form USD Million (2018-2023)
  • Table 84. Italy Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 85. Italy Lisinopril , by Dosage USD Million (2018-2023)
  • Table 86. United Kingdom Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 87. United Kingdom Lisinopril , by Form USD Million (2018-2023)
  • Table 88. United Kingdom Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 89. United Kingdom Lisinopril , by Dosage USD Million (2018-2023)
  • Table 90. Netherlands Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 91. Netherlands Lisinopril , by Form USD Million (2018-2023)
  • Table 92. Netherlands Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 93. Netherlands Lisinopril , by Dosage USD Million (2018-2023)
  • Table 94. Rest of Europe Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 95. Rest of Europe Lisinopril , by Form USD Million (2018-2023)
  • Table 96. Rest of Europe Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 97. Rest of Europe Lisinopril , by Dosage USD Million (2018-2023)
  • Table 98. MEA Lisinopril , by Country USD Million (2018-2023)
  • Table 99. MEA Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 100. MEA Lisinopril , by Form USD Million (2018-2023)
  • Table 101. MEA Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 102. MEA Lisinopril , by Dosage USD Million (2018-2023)
  • Table 103. Middle East Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 104. Middle East Lisinopril , by Form USD Million (2018-2023)
  • Table 105. Middle East Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 106. Middle East Lisinopril , by Dosage USD Million (2018-2023)
  • Table 107. Africa Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 108. Africa Lisinopril , by Form USD Million (2018-2023)
  • Table 109. Africa Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 110. Africa Lisinopril , by Dosage USD Million (2018-2023)
  • Table 111. North America Lisinopril , by Country USD Million (2018-2023)
  • Table 112. North America Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 113. North America Lisinopril , by Form USD Million (2018-2023)
  • Table 114. North America Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 115. North America Lisinopril , by Dosage USD Million (2018-2023)
  • Table 116. United States Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 117. United States Lisinopril , by Form USD Million (2018-2023)
  • Table 118. United States Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 119. United States Lisinopril , by Dosage USD Million (2018-2023)
  • Table 120. Canada Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 121. Canada Lisinopril , by Form USD Million (2018-2023)
  • Table 122. Canada Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 123. Canada Lisinopril , by Dosage USD Million (2018-2023)
  • Table 124. Mexico Lisinopril , by Patient Age USD Million (2018-2023)
  • Table 125. Mexico Lisinopril , by Form USD Million (2018-2023)
  • Table 126. Mexico Lisinopril , by Sales Channel USD Million (2018-2023)
  • Table 127. Mexico Lisinopril , by Dosage USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Lisinopril : by Patient Age(USD Million)
  • Table 139. Lisinopril  Paediatric (6 to 17 years) , by Region USD Million (2025-2030)
  • Table 140. Lisinopril  Adult (above 18 years) , by Region USD Million (2025-2030)
  • Table 141. Lisinopril : by Form(USD Million)
  • Table 142. Lisinopril  Solution , by Region USD Million (2025-2030)
  • Table 143. Lisinopril  Tablet , by Region USD Million (2025-2030)
  • Table 144. Lisinopril : by Sales Channel(USD Million)
  • Table 145. Lisinopril  Online , by Region USD Million (2025-2030)
  • Table 146. Lisinopril  Offline , by Region USD Million (2025-2030)
  • Table 147. Lisinopril  Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 148. Lisinopril  Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 149. Lisinopril : by Dosage(USD Million)
  • Table 150. Lisinopril  2.5 mg , by Region USD Million (2025-2030)
  • Table 151. Lisinopril  5 mg , by Region USD Million (2025-2030)
  • Table 152. Lisinopril  10 mg , by Region USD Million (2025-2030)
  • Table 153. Lisinopril  20 mg , by Region USD Million (2025-2030)
  • Table 154. Lisinopril  30 mg , by Region USD Million (2025-2030)
  • Table 155. Lisinopril  40 mg , by Region USD Million (2025-2030)
  • Table 156. South America Lisinopril , by Country USD Million (2025-2030)
  • Table 157. South America Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 158. South America Lisinopril , by Form USD Million (2025-2030)
  • Table 159. South America Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 160. South America Lisinopril , by Dosage USD Million (2025-2030)
  • Table 161. Brazil Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 162. Brazil Lisinopril , by Form USD Million (2025-2030)
  • Table 163. Brazil Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 164. Brazil Lisinopril , by Dosage USD Million (2025-2030)
  • Table 165. Argentina Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 166. Argentina Lisinopril , by Form USD Million (2025-2030)
  • Table 167. Argentina Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 168. Argentina Lisinopril , by Dosage USD Million (2025-2030)
  • Table 169. Rest of South America Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 170. Rest of South America Lisinopril , by Form USD Million (2025-2030)
  • Table 171. Rest of South America Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 172. Rest of South America Lisinopril , by Dosage USD Million (2025-2030)
  • Table 173. Asia Pacific Lisinopril , by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 175. Asia Pacific Lisinopril , by Form USD Million (2025-2030)
  • Table 176. Asia Pacific Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 177. Asia Pacific Lisinopril , by Dosage USD Million (2025-2030)
  • Table 178. China Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 179. China Lisinopril , by Form USD Million (2025-2030)
  • Table 180. China Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 181. China Lisinopril , by Dosage USD Million (2025-2030)
  • Table 182. Japan Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 183. Japan Lisinopril , by Form USD Million (2025-2030)
  • Table 184. Japan Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 185. Japan Lisinopril , by Dosage USD Million (2025-2030)
  • Table 186. India Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 187. India Lisinopril , by Form USD Million (2025-2030)
  • Table 188. India Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 189. India Lisinopril , by Dosage USD Million (2025-2030)
  • Table 190. South Korea Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 191. South Korea Lisinopril , by Form USD Million (2025-2030)
  • Table 192. South Korea Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 193. South Korea Lisinopril , by Dosage USD Million (2025-2030)
  • Table 194. Taiwan Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 195. Taiwan Lisinopril , by Form USD Million (2025-2030)
  • Table 196. Taiwan Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 197. Taiwan Lisinopril , by Dosage USD Million (2025-2030)
  • Table 198. Australia Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 199. Australia Lisinopril , by Form USD Million (2025-2030)
  • Table 200. Australia Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 201. Australia Lisinopril , by Dosage USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Lisinopril , by Form USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Lisinopril , by Dosage USD Million (2025-2030)
  • Table 206. Europe Lisinopril , by Country USD Million (2025-2030)
  • Table 207. Europe Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 208. Europe Lisinopril , by Form USD Million (2025-2030)
  • Table 209. Europe Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 210. Europe Lisinopril , by Dosage USD Million (2025-2030)
  • Table 211. Germany Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 212. Germany Lisinopril , by Form USD Million (2025-2030)
  • Table 213. Germany Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 214. Germany Lisinopril , by Dosage USD Million (2025-2030)
  • Table 215. France Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 216. France Lisinopril , by Form USD Million (2025-2030)
  • Table 217. France Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 218. France Lisinopril , by Dosage USD Million (2025-2030)
  • Table 219. Italy Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 220. Italy Lisinopril , by Form USD Million (2025-2030)
  • Table 221. Italy Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 222. Italy Lisinopril , by Dosage USD Million (2025-2030)
  • Table 223. United Kingdom Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 224. United Kingdom Lisinopril , by Form USD Million (2025-2030)
  • Table 225. United Kingdom Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 226. United Kingdom Lisinopril , by Dosage USD Million (2025-2030)
  • Table 227. Netherlands Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 228. Netherlands Lisinopril , by Form USD Million (2025-2030)
  • Table 229. Netherlands Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 230. Netherlands Lisinopril , by Dosage USD Million (2025-2030)
  • Table 231. Rest of Europe Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 232. Rest of Europe Lisinopril , by Form USD Million (2025-2030)
  • Table 233. Rest of Europe Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 234. Rest of Europe Lisinopril , by Dosage USD Million (2025-2030)
  • Table 235. MEA Lisinopril , by Country USD Million (2025-2030)
  • Table 236. MEA Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 237. MEA Lisinopril , by Form USD Million (2025-2030)
  • Table 238. MEA Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 239. MEA Lisinopril , by Dosage USD Million (2025-2030)
  • Table 240. Middle East Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 241. Middle East Lisinopril , by Form USD Million (2025-2030)
  • Table 242. Middle East Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 243. Middle East Lisinopril , by Dosage USD Million (2025-2030)
  • Table 244. Africa Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 245. Africa Lisinopril , by Form USD Million (2025-2030)
  • Table 246. Africa Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 247. Africa Lisinopril , by Dosage USD Million (2025-2030)
  • Table 248. North America Lisinopril , by Country USD Million (2025-2030)
  • Table 249. North America Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 250. North America Lisinopril , by Form USD Million (2025-2030)
  • Table 251. North America Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 252. North America Lisinopril , by Dosage USD Million (2025-2030)
  • Table 253. United States Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 254. United States Lisinopril , by Form USD Million (2025-2030)
  • Table 255. United States Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 256. United States Lisinopril , by Dosage USD Million (2025-2030)
  • Table 257. Canada Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 258. Canada Lisinopril , by Form USD Million (2025-2030)
  • Table 259. Canada Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 260. Canada Lisinopril , by Dosage USD Million (2025-2030)
  • Table 261. Mexico Lisinopril , by Patient Age USD Million (2025-2030)
  • Table 262. Mexico Lisinopril , by Form USD Million (2025-2030)
  • Table 263. Mexico Lisinopril , by Sales Channel USD Million (2025-2030)
  • Table 264. Mexico Lisinopril , by Dosage USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lisinopril : by Patient Age USD Million (2018-2023)
  • Figure 5. Global Lisinopril : by Form USD Million (2018-2023)
  • Figure 6. Global Lisinopril : by Sales Channel USD Million (2018-2023)
  • Figure 7. Global Lisinopril : by Dosage USD Million (2018-2023)
  • Figure 8. South America Lisinopril  Share (%), by Country
  • Figure 9. Asia Pacific Lisinopril  Share (%), by Country
  • Figure 10. Europe Lisinopril  Share (%), by Country
  • Figure 11. MEA Lisinopril  Share (%), by Country
  • Figure 12. North America Lisinopril  Share (%), by Country
  • Figure 13. Global Lisinopril  share by Players 2023 (%)
  • Figure 14. Global Lisinopril  share by Players (Top 3) 2023(%)
  • Figure 15. Global Lisinopril  share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 18. Lupin (India) Revenue: by Geography 2023
  • Figure 19. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 21. Zhejiang Huahai Pharmaceutical Co. (China) Revenue, Net Income and Gross profit
  • Figure 22. Zhejiang Huahai Pharmaceutical Co. (China) Revenue: by Geography 2023
  • Figure 23. Actavis, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Actavis, Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Apotex Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Apotex Inc. (Canada) Revenue: by Geography 2023
  • Figure 27. Sun Pharmaceuticals Inc. (India) Revenue, Net Income and Gross profit
  • Figure 28. Sun Pharmaceuticals Inc. (India) Revenue: by Geography 2023
  • Figure 29. Evonik Industries (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Evonik Industries (Germany) Revenue: by Geography 2023
  • Figure 31. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Sandoz (a Novartis company) (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Sandoz (a Novartis company) (Switzerland) Revenue: by Geography 2023
  • Figure 35. Silvergate Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Silvergate Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Lisinopril : by Patient Age USD Million (2025-2030)
  • Figure 38. Global Lisinopril : by Form USD Million (2025-2030)
  • Figure 39. Global Lisinopril : by Sales Channel USD Million (2025-2030)
  • Figure 40. Global Lisinopril : by Dosage USD Million (2025-2030)
  • Figure 41. South America Lisinopril  Share (%), by Country
  • Figure 42. Asia Pacific Lisinopril  Share (%), by Country
  • Figure 43. Europe Lisinopril  Share (%), by Country
  • Figure 44. MEA Lisinopril  Share (%), by Country
  • Figure 45. North America Lisinopril  Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Lupin (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Zhejiang Huahai Pharmaceutical Co. (China)
  • Actavis, Inc. (United States)
  • Apotex Inc. (Canada)
  • Sun Pharmaceuticals Inc. (India)
  • Evonik Industries (Germany)
  • AstraZeneca PLC (United Kingdom)
  • Sandoz (a Novartis company) (Switzerland)
  • Silvergate Pharmaceuticals, Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 247 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lisinopril  Market Quantitative research analysis
Global Lisinopril  Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Lisinopril  Market are by end use application [].
The Lisinopril  Market is gaining popularity and expected to see strong valuation by 2030.
  • Growing prevalence of cardiac arrest
  • Rise in geriatric population experiencing higher rates of hypertension.

Know More About Global Lisinopril  Market Report?

Have a Query? Click Here

Other Related Reports

Dosulepin Comprehensive Study by Type (Tablets (75mg), Capsules (25mg)), Application (Depression Treatment, Anxiety Treatment, Others), Distribution Channel (Hospital, Drug Store, Online Store) Playe...
$ 3500
Adenovirus Vector Vaccine Comprehensive Study by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine, Others), Application (Human, Animals), ...
$ 3450
Goserelin Drug Comprehensive Study by Indication (Prostate Cancer, Breast Cancer, Endometriosis, Gynaecological Disorders), Sales Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Dose (...
$ 3500
Paediatric Palliative Care Drugs Comprehensive Study by Type (Paracetamol, Ibuprofen, Morphine, Others), Route of Administration (Oral, Topical, Parenteral), Distribution Channel (Hospital Pharmacies...
$ 3450
Drug Repurposing Comprehensive Study by Type (De novo drug discovery, Personalized Medicine, Genomics, Gene Editing), Application (Discovering drug targets,, Identifying and optimizing lead compounds...
$ 3650
Cyclobenzaprine Comprehensive Study by Patient Type (Adult, Pediatric), Form (Tablet, Capsule), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies), Dosage (5 mg, 7.5 mg,...
$ 3350